Mantle Cell Lymphoma News

Biovest Announces BiovaxID(R) ASCO Abstract Available On-line; NCI to Present ... - MarketWatch (press release)



Biovest Announces BiovaxID(R) ASCO Abstract Available On-line; NCI to Present ... 
MarketWatch (press release)
The abstract (#2528), titled, "Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL)", is now available on-line at the ASCO website at: ...
Biovest makes a move on the EU market with BiovaxID FierceVaccines

all 13 news articles » 


Identifying Appropriate Patient Groups and Drug Targets in DLBCL - Cancer Network



Identifying Appropriate Patient Groups and Drug Targets in DLBCL 
Cancer Network
By Brian K. Link, MD 1 | May 15, 2012 In their article in this issue of ONCOLOGY, Nastoupil, Rose, and Flowers give a very careful assessment of the options for treating diffuse large B-cell lymphoma (DLBCL), with a focus on the importance of dose ...

and more » 


/C O R R E C T I O N -- Amgen/ - MarketWatch (press release)



/C O R R E C T I O N -- Amgen/ 
MarketWatch (press release)
Blinatumomab targets cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas, such as ALL. Full results of the study will be presented during an oral abstract session at the 48th Annual Meeting of the American ...

and more » 


Biovest to Seek Marketing Approval in the EU for BiovaxID(R) Personalized ... - MarketWatch (press release)



Biovest to Seek Marketing Approval in the EU for BiovaxID(R) Personalized ... 
MarketWatch (press release)
EMA approval would establish BiovaxID as the first cancer vaccine available in Europe for lymphoma patients. Biovest based its decision to pursue EU marketing approval on pre-filing clinical advisory meetings with EU-member national regulatory agencies ...

and more » 


ZYTIGAŽ (abiraterone acetate) Data to be Presented at 2012 American Society of ... - MarketWatch (press release)



ZYTIGAŽ (abiraterone acetate) Data to be Presented at 2012 American Society of ... 
MarketWatch (press release)
About Ibrutinib (formerly PCI-32765)Ibrutinib is a first-in-class oral, selective Bruton's tyrosine kinase (Btk) inhibitor being investigated for its potential in treating patients with chronic lymphocytic leukemia, Mantle Cell lymphoma, diffuse large ...

and more » 


Onconova Advances Oral Rigosertib to Phase II Clinical Trial in ... - MarketWatch (press release)



Onconova Advances Oral Rigosertib to Phase II Clinical Trial in ... 
MarketWatch (press release)
Na (Ex-RAD(R)), a radioprotectant, and ON 013105, a novel anticancer agent initially directed to refractory lymphoma, including Mantle Cell Lymphoma. For additional information, please visit http://www.onconova.com .

and more » 


Biovest Retains Ferghana Partners to Evaluate Strategic Transactions - MarketWatch (press release)



Biovest Retains Ferghana Partners to Evaluate Strategic Transactions 
MarketWatch (press release)
Moreover, BiovaxID provides substantial and durable clinical efficacy with the Phase III clinical trial demonstrating that BiovaxID significantly improves disease-free survival in follicular lymphoma and the Phase II mantle cell lymphoma clinical trial ...

and more » 


Biovest Announces that New Clinical Data for BiovaxID(R) Personalized Cancer ... - MarketWatch (press release)



Biovest Announces that New Clinical Data for BiovaxID(R) Personalized Cancer ... 
MarketWatch (press release)
MINNEAPOLIS, May 03, 2012 (BUSINESS WIRE) -- Biovest International, Inc. (otcqb:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (otcqb:ABPI), today announced that new data from the BiovaxID(R) Phase II mantle cell lymphoma ...

and more » 


Meeting the Challenges in Treating Lymphoma A Conversation With Andrew D ... - OncLive



OncLive 
Meeting the Challenges in Treating Lymphoma A Conversation With Andrew D ... 
OncLive
OBTN: How effective are today's available treatments for non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma? Dr Zelenetz: The standard of care for diffuse large B-cell lymphoma (DLBCL) in the United States remains rituximab (R) in ...

 


Combination of Lenalidomide and SNS01-T Effective in Cancer Model - MarketWatch (press release)



Combination of Lenalidomide and SNS01-T Effective in Cancer Model 
MarketWatch (press release)
The Company recently reported that SNS01-T significantly inhibits the growth of both human mantle cell and diffuse large B-cell lymphomas in mouse xenograft models and that the combination of lenalidomide and SNS01-T, performs better than either ...

and more »